Pipeline news

• Marinus Pharmaceuticals Announces $32.5 Million Revenue Interest Financing Agreement with Sagard Healthcare Partners

  31 October 2022

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has entered into a revenue interest financing agreement with Sagard Healthcare Partners for a total of $32.5 million upfront in return for payments based on U.S. net sales of ganaxolone, including the recently approved ZTALMY^® (ganaxolone) oral suspension CV.

• Self-Collection Kits Provide Convenient Care for Sexually Transmitted Infections for Residents in All Alabama Counties

  04 October 2022

  

  In a first of its kind partnership, the Alabama Department of Public Health (ADPH) and binx health, a healthcare technology and diagnostics company, enables access to routine remote sample collection for sexually transmitted infections (STIs) and subsequent treatment for Alabama residents.

• PC-002 International Multicenter Phase II Clinical Trial in Beijing Cancer Hospital Launches Patient Recruitment

  29 September 2022

  

  Recently, Cothera Bioscience, the parent company of Percans Oncology, has made new progress in the Phase II clinical trial of MYC gene inhibitor PC-002 in China. Beijing Cancer Hospital is conducting a multicenter, open-label, exploratory dose-ranging phase II study of Sepantronium Bromide in patients with relapsed/refractory c-Myc rearranged high-grade B-cell lymphoma (HGBCL) (clinical trial approval number: 2022LP00392). 

• Marinus Pharmaceuticals Announces Exercise of First Contract Option by the Biomedical Advanced Research and Development Authority (BARDA)

  22 September 2022

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, exercised its first contract option, valued at approximately $12.3 million, to support U.S. onshoring of the manufacturing capabilities for ganaxolone active pharmaceutical ingredient (API).

• Marinus Pharmaceuticals Announces Closing of Sale of Priority Review Voucher for $110 Million

  30 August 2022

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has closed on the sale of its Rare Pediatric Disease Priority Review Voucher for $110 million. The $110 million of gross funds have been received and are in addition to the $92.3 million in cash and cash equivalents reported as of June 30, 2022.

• Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

  11 August 2022

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the second quarter ended June 30, 2022.

• Marinus Pharmaceuticals Announces U.S. Commercial Launch of ZTALMY® (ganaxolone) for Seizures Associated With CDKL5 Deficiency Disorder

  28 July 2022

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the U.S. commercial launch of ZTALMY^® (ganaxolone) oral suspension, CV for the treatment of seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older.

• Marinus Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher for $110 Million

  14 July 2022

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $110 million.

• Marinus Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher for $110 Million

  14 July 2022

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $110 million.

• binx health CEO, Jeffrey Luber announced as an EY Entrepreneur Of The Year 2022® New England Award Winner

  09 June 2022

  

  Ernst & Young LLP (EY US) today announced that Jeffrey Luber, Chief Executive Officer of binx health, was named an Entrepreneur Of The Year® 2022 New England Award winner. Entrepreneur Of The Year® is one of the preeminent competitive business awards for entrepreneurs and leaders of high-growth companies who think big to succeed. An independent panel of judges selected Jeffrey Luber based on his entrepreneurial spirit, purpose, growth, and impact, among other core contributions and attributes.